There is really no portion of American life that the Hemp for Victory bill does not touch. It seeks to study the potential uses of hemp across all sectors of our economy.
Regardless of how the FDA will eventually regulate CBD, it is abundantly clear that CBD companies should not make medical/disease claims nor market their products as dietary supplements. Doing so at this point is simply foolish.
This article discusses the reasons for smokable hemp’s rapid rise in popularity, why the future of smokable hemp is vital to the hemp industry at large, and the ways in which its legal status is under attack in several states.
The entire hemp industry is anxiously awaiting guidance from the United States Department of Agriculture (USDA). This wait has created a vacuum of sorts that many state legislatures are beginning to fill.
Employers in most states still have the right to discriminate against cannabis users in pre-employment drug screenings. The exception is the state of Nevada, which passed legislation banning the disqualification of a candidate for employment based on cannabis use.
As anyone involved in the cannabis industry is aware, the US Food and Drug Administration (FDA) held hearings on May 31, 2019. Ostensibly, the hearing was about “Products Containing Cannabis or Cannabis-Derived Compounds”. In reality, it was about cannabidiol (CBD) in foods, cosmetics, and dietary supplements.
My client’s interaction with DHL reiterates my view that it is usually best to ship hemp and hemp products through the US Postal Service.
On June 6, an update from the United States Postal Service (USPS) arrived with new and more straightforward guidelines for mailing hemp and CBD in the United States.
Texas finally came around and enacted House Bill 1325 (HB1325), which regulates hemp production in the state. The law went into effect last night.
I spoke with Elijah Wolfson of Time Magazine about CBD after the FDA hearing. We spoke about several issues, including how to regulate CBD for mass market consumption while protecting the integrity of the clinical drug trials process.